Clinical trial

Chidamide Combined With Cisplatin for Relapsed or Metastatic Triple-negative Breast Cancer

NCT04192903

Drugs and interventions used in this trial

1 registered

These interventions are listed by ClinicalTrials.gov. An RxNorm link indicates a mapped medicine record; the registry name alone is not proof of a specific branded formulation.

Search this trial's interventions

DRUG · Unmapped registry intervention Chidamide combined with Cisplatin Find medicine records · Find other trials using this name

Study at a glance

Registry-backed

Chidamide Combined With Cisplatin for Relapsed or Metastatic Triple-negative Breast Cancer

Design: INTERVENTIONAL · Status: UNKNOWN · Phase: PHASE2

Read study objectives, eligibility and outcome measures at ClinicalTrials.gov

StatusUNKNOWN

Study typeINTERVENTIONAL

Start date2019-12-25

PhasePHASE2

Conditions

Triple-negative Breast Cancerverified · MONDO: triple-negative breast carcinoma

Interventions

Chidamide combined with CisplatinDRUG

Sponsors & collaborators

Fudan Universitylead sponsor

Mapped research locations

ShanghaiChina2

Registry source

Open the source record to verify current eligibility, contacts, locations and registry updates.

Open NCT04192903 on ClinicalTrials.gov ↗

Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.